SECOND QUARTER 2025 EARNINGS PRESENTATION JULY 24, 2025 SAFE HARBOR STATEMENT This presentation includes "forward-looking" statements that involve risks and uncertainties that are generally identifiable through the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," "should," "will," "may," "outlook," and other words and similar expressions and include projections of earnings. The forward-looking statements in this presentation are made pursuant to the safe harbo ...

Nokia CorporationInside information22 July 2025 at 19:00 EESTInside Information: Nokia lowers 2025 operating profit guidance due to currency   Nokia lowers its comparable operating profit guidance range to EUR 1.6 billion to EUR 2.1 billion from EUR 1.9 billion to EUR 2.4 billion.  Adjustment relates to currency headwinds from the weaker USD and tariffs. Reports preliminary Q2 financial results of approximately EUR 4.55 billion net sales and EUR 0.3 billion comparable operating profit.   Espoo, Finland – No ...

Release no. 11/2025 July 16th, 2025Columbus adjusts financial guidance for 2025 Company announcement Adjusted financial guidance for 2025 Columbus A/S announces adjustment of the full-year guidance for 2025. Overall, we are facing a challenging macro-economic environment that negatively impacts our customers’ decision-making in major IT projects, resulting in postponement of projects and extended sales processes. Due to the expected continued marked uncertainty, Columbus adjusts the full-year guidance for 2 ...

Core Viewpoint - Gray Media, Inc. has updated its financial guidance for the quarter ended June 30, 2025, indicating a decline in total revenue compared to the same quarter in 2024, alongside other significant developments affecting its financial position [2][3][4]. Financial Guidance Summary - The anticipated total revenue for the quarter ended June 30, 2025, is projected to be between $769 million and $775 million, a decrease from $826 million in the same quarter of 2024 [2]. - Core advertising revenue is expected to decline to between $360 million and $362 million from $373 million in the previous year [2]. - Political advertising revenue is forecasted to drop significantly to between $8 million and $9 million, down from $47 million [2]. - Retransmission consent revenue is expected to remain relatively stable, projected between $368 million and $369 million compared to $371 million [2]. - Total operating expenses for broadcasting are anticipated to remain flat at approximately $565 million, with slight variations in station expenses and network affiliation fees [2]. Debt Management Actions - In June 2025, Gray repurchased $7.7 million of its 5.875% senior notes due 2026, and made amortization payments totaling $15 million on its Term Loans D and F, fulfilling all mandatory obligations through December 31, 2025 [3]. Impairment Charge - Gray expects to record a non-cash impairment charge of approximately $29 million in Q2 2025 related to intangible assets from its Atlanta station, WANF, due to its cessation of CBS network affiliation effective August 16, 2025 [4][5].

Financial Performance - Total revenue for Q4 2018 was $166.5 million, a 13% increase compared to $147.7 million in Q4 2017[73] - Net income attributable to common shareholders for Q4 2018 was $48.0 million, a 12% decrease compared to $54.7 million in Q4 2017[73] - FFO (Funds From Operations) attributable to common shareholders for Q4 2018 was $97.7 million, a 25% increase compared to $78.0 million in Q4 2017[73] - Adjusted FFO attributable to common shareholders for Q4 2018 was $105.1 million, a 10% increase compared to $95.9 million in Q4 2017[73] - Total revenue for 2018 was $700.7 million, a 22% increase compared to $576.0 million in 2017[76] - Net income attributable to common shareholders for 2018 was $242.8 million, a 4% increase compared to $234.2 million in 2017[76] - FFO attributable to common shareholders for 2018 was $414.3 million, a 27% increase compared to $327.4 million in 2017[76] - Adjusted FFO attributable to common shareholders for 2018 was $460.4 million, a 28% increase compared to $360.5 million in 2017[76] Portfolio and Investments - Total investments reached $6.8 billion[28] - The company owns 394 properties in service with 99% occupancy[28] - Q4 2018 investment spending was $217 million[28] - 2018 investment spending totaled $572 million[28]

Core Insights - Post Holdings, Inc. reported second-quarter fiscal 2025 results with net sales missing estimates but adjusted earnings exceeding expectations, both metrics showing year-over-year declines [1][2]. Financial Performance - Adjusted earnings per share were $1.41, surpassing the Zacks Consensus Estimate of $1.18, but down from $1.51 in the prior year [2]. - Net sales totaled $1,952.1 million, a 2.3% decrease year over year, missing the Zacks Consensus Estimate of $1,977 million [2]. - Gross profit was $545.8 million, down 5.8% year over year, with gross margin contracting to 28% from 29% [3]. - Selling, general and administrative expenses decreased by 7.8% to $314.8 million, representing 16.1% of net sales compared to 17.1% in the previous year [3]. - Operating profit decreased by 4.2% to $182.2 million, while adjusted EBITDA increased by 0.4% to $346.5 million [3]. Segment Performance - **Post Consumer Brands**: Net sales were $987.9 million, down 7.3% year over year, missing estimates. Volumes fell by 5.8%, with cereal volumes down 6.3% [4]. - **Weetabix**: Reported a 4.6% decline in net sales to $131.7 million, missing estimates. Volumes decreased by 7.1% [5]. - **Foodservice**: Achieved 9.6% growth in net sales to $607.9 million, surpassing estimates. Volumes grew by 2.8% [6]. - **Refrigerated Retail**: Sales dipped 6.6% to $224.6 million, missing estimates. Volumes dropped by 4.9% [7]. Other Financial Aspects - Cash and cash equivalents stood at $617.6 million, with long-term debt of $6,944.6 million and total shareholders' equity of $3,841.4 million [8]. - The company repurchased 1.7 million shares for $191.6 million in the second quarter, totaling 3.3 million shares for $372.7 million in the first half of fiscal 2025 [9][10]. Future Guidance - Post Holdings updated its fiscal 2025 adjusted EBITDA guidance to a range of $1,430-$1,470 million, up from the previous range of $1,420-$1,460 million [11]. - Expected capital expenditures for fiscal 2025 are between $390 million and $430 million, including significant investments in Post Consumer Brands and Foodservice [12].

Q1 2025 Earnings May 8, 2025 1 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2025 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Forward Looking Statements This presentation contains "forward-looking statements". These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of ...

Core Insights - Cencora, Inc reported a 10.3% increase in second-quarter 2025 sales to $75.5 billion, slightly missing the consensus estimate of $75.68 billion, primarily driven by an 11.4% revenue increase in the U.S. Healthcare Solutions segment [1] Financial Performance - U.S. Healthcare Solutions revenue reached $68.3 billion, attributed to market growth driven by unit volume increases, particularly in diabetes and weight loss products in the GLP-1 class, as well as specialty products sold to physician practices and health systems [2] - Adjusted EPS for the quarter was $4.42, reflecting a 16.3% year-over-year increase, surpassing the consensus estimate of $4.11 [2] - Adjusted gross profit for the second quarter was $2.9 billion, a 15.2% increase year-over-year, mainly due to growth in the U.S. Healthcare Solutions segment, although partially offset by a decline in the International Healthcare Solutions segment [3] - Adjusted gross profit margin improved to 3.86%, up 16 basis points, while adjusted operating income rose to $1.2 billion, a 15.3% increase, driven by the U.S. Healthcare Solutions segment [4] Guidance and Outlook - Cencora updated its fiscal year 2025 financial guidance, projecting adjusted diluted EPS between $15.70 and $15.95, an increase from the previous range of $15.30 to $15.60, compared to the consensus of $15.46 [5] - Revenue growth for the International Healthcare Solutions segment is now expected to be between 3% and 4%, down from the previous estimate of 4% to 5% [5] - Adjusted consolidated operating income growth is anticipated to be between 13.5% and 15.5%, an increase from the prior range of 11.5% to 13.5% [6]

Core Viewpoint - Valneva SE reported strong financial results for Q1 2025, with significant revenue growth and reduced operational cash burn, while confirming its financial guidance for the year [3][5][6]. Financial Performance - Total revenues for Q1 2025 were €49.2 million, a 50.3% increase from €32.8 million in Q1 2024 [5][6]. - Product sales reached €48.6 million, up 51.2% from €32.1 million in the same period last year [6][31]. - The company reported a net loss of €9.2 million compared to a net profit of €58.9 million in Q1 2024, which included €90.8 million from the sale of a Priority Review Voucher [6][45]. - Operating cash burn was reduced by 71% to €8.1 million in Q1 2025 from €28.4 million in Q1 2024 [6][47]. - Cash and cash equivalents stood at €153.0 million as of March 31, 2025, down from €168.3 million at the end of 2024 [6][50]. Product Sales and Market Developments - IXIARO®/JESPECT® sales increased by 65.5% to €27.5 million, driven by demand from travelers and the U.S. Department of Defense [10][32]. - DUKORAL® sales grew 9.4% to €12.3 million, supported by a supply agreement with the French government [12][33]. - IXCHIQ® sales surged to €3.0 million from €0.2 million in Q1 2024, with initial sales related to a chikungunya outbreak response [13][34]. - Third-party product sales increased to €5.8 million from €4.1 million, reflecting recovery from previous supply constraints [18][35]. Research and Development Highlights - Valneva is advancing its Lyme disease vaccine candidate, VLA15, with primary vaccinations completed and data expected by the end of 2025 [20][21]. - The company is also developing a tetravalent Shigella vaccine candidate, S4V2, with ongoing Phase 2 studies [23][24]. - A Phase 1 trial for a Zika vaccine candidate, VLA1601, is currently underway, with results anticipated this year [28][29]. Strategic Partnerships and Regulatory Progress - Valneva secured a $32.8 million supply contract for IXIARO® with the U.S. Department of Defense [7][11]. - The company received marketing authorization for IXCHIQ® in the UK and Brazil, marking significant milestones for its chikungunya vaccine [7][14][15]. - Valneva has entered into a licensing agreement with the Serum Institute of India to expand access to its chikungunya vaccine in Asia [15][61]. Financial Outlook - The company expects product sales to grow to €170-180 million in 2025, with total revenues projected to reach €180-190 million [6][5]. - R&D investments are anticipated to be between €90-100 million in 2025, partially offset by grant funding and tax credits [6][5].

Core Insights - Halozyme Therapeutics reported a strong financial performance for Q1 2025, with total revenue increasing by 35% year-over-year to $265 million, driven by a 39% increase in royalty revenue to $168 million [1][8] - The company announced a new $250 million share repurchase program, part of a larger $750 million initiative approved in February 2024 [6][2] - Halozyme raised its financial guidance for 2025, projecting total revenue between $1,200 million and $1,280 million, representing year-over-year growth of 18% to 26% [1][11] Financial Performance - Net income for Q1 2025 increased by 54% year-over-year to $118 million, with adjusted EBITDA rising by 40% to $162 million [1][8] - GAAP diluted EPS rose by 55% year-over-year to $0.93, while non-GAAP diluted EPS increased by 41% to $1.11 [1][8] - Cash, cash equivalents, and marketable securities totaled $747.9 million as of March 31, 2025, up from $596.1 million at the end of 2024 [8] Product and Pipeline Developments - The company highlighted strong growth from its three blockbuster brands: Darzalex SC, Phesgo, and VYVGART Hytrulo, along with contributions from four recently launched products [2][3] - Halozyme's pipeline includes two products in Phase 3 trials, with ongoing development and progress reported by partners [3][2] - Recent approvals and positive opinions from regulatory bodies for various products are expected to create additional growth catalysts [6][9] Corporate Activities - Halozyme filed a patent infringement lawsuit against Merck for alleged use of its MDASE™ technology in developing Subcutaneous Keytruda [6] - The company completed its first $250 million accelerated share repurchase under the approved program in March 2025 [6][2] - Recent corporate highlights include positive regulatory developments for Phesgo® and VYVGART® in Europe and the U.S. [6][9]